Cell Pathways
Cell Pathways, Inc. (CPI) was a development-stage pharmaceutical company headquartered at 702 Electronic Drive, Horsham, Pennsylvania, focused on the research and development of products to treat and prevent cancer. Incorporated in Delaware in July 1998 (as Cell Pathways Holdings, Inc., renamed Cell Pathways, Inc. in February 2001), it developed a class of compounds it called selective apoptotic anti-neoplastic drugs (SAANDs), designed to induce selective apoptosis — programmed cell death — in precancerous and cancerous cells without affecting normal cells. Its lead candidate was Aptosyn (exisulind), studied in precancerous lesions such as colonic polyps and cervical dysplasia and later in prostate, lung, and breast cancer; the company also imported, promoted, and sold Gelclair Concentrated Oral Gel into oncology and dental markets, and had previously marketed Nilandron. It traded on the Nasdaq National Market (Commission File No. 000-24889) and employed approximately 34 people full-time as of March 1, 2003. In February 2003 Cell Pathways signed an Agreement and Plan of Merger to be acquired by OSI Pharmaceuticals, Inc. in a stock-for-stock exchange; stockholders approved the merger on June 10, 2003, and the company filed a Form 15-12G on June 12, 2003 terminating its Exchange Act registration with one holder of record. OSI Pharmaceuticals was itself acquired by Astellas Pharma and deregistered on June 18, 2010. Cell Pathways predates the API economy entirely, never operated a developer program or public API surface, and no longer exists as an operating entity. This profile is retained as an acquired-company lead with no API surface to enrich.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
Cell Pathways is tracked in the API Evangelist network. This page is the human-readable profile that sits on top of the machine-readable index we maintain at apis.io.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Cell Pathways scores 5.7/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
Resources
Every other property we hold for Cell Pathways — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Other 2
Properties that don't map to a standard resource type
Cell Pathways is in the network as a tracked entity. We haven't yet indexed a public API surface for it — when one is published, the artifacts, score, and agent-readiness read will appear here automatically. The source repository is where that profile is built.
← All providers · Data indexed from github.com/api-evangelist/cell-pathways · machine-readable index on apis.io